Kura Oncology Inc - Company Profile
Powered by 
All the sales intelligence you need on Kura Oncology Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kura Oncology Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kura Oncology Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kura Oncology Inc (Kura Oncology) is a biotechnology company that discovers and develops novel cancer therapeutics. It carries out advancing precision medicines designed to target cancer cells selectively, aiming to improve patient outcomes. The company's major products include small molecule drug candidates such as menin inhibitors and farnesyl transferase inhibitors. Kura Oncology's pipeline products include precision medicines such as Ziftomenib, Tipifarnib, and KO-2806, among others. The company's products are primarily used in the healthcare industry, specifically in the treatment of blood cancers and solid tumors. It collaborates with clinical, laboratory, and molecular pathology partners to integrate biomarker testing into its clinical trials. Kura Oncology is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
Suite 500, 4930 Directors Place, San Diego, California, 92121
Website
www.kuraoncology.com
Telephone
1 858 5008800
No of Employees
260
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KURA (NASD)
Revenue (2024)
$67.5M
25.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-60.2%
(2024 vs 2023)
Market Cap*
$964.1M
Net Profit Margin (2024)
XYZ
-27.9%
(2024 vs 2023)
* As of and is in US$
Kura Oncology Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Ziftomenib: |
| Acute Lymphoblastic Leukemia |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Asset Disposal | In December, the company sold its US Food and Drug Administration-approved leukemia drug KOMZIFTI (ziftomenib). |
| 2025 | Regulatory Approval | In November, the company and Kyowa Kirin Co secured full approval of KOMZIFTI (ziftomenib) for adult patients with relapsed or refractory (R/R) acute myeloid leukemia. |
| 2025 | Regulatory Approval | In April, the company and Kyowa Kirin Co., Ltd. announced that Kura submitted an application to the US Food and Drug Administration for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia with a nucleophosmin 1 (NPM 1) mutation. |
Competitor Comparison
| Key Parameters | Kura Oncology Inc | Gyre Therapeutics Inc | Spectrum Pharmaceuticals Inc | BioMed Valley Discoveries Inc | Otsuka America Pharmaceutical Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Diego | San Diego | Lake Forest | Kansas City | Rockville |
| State/Province | California | California | Illinois | Missouri | Maryland |
| No. of Employees | 260 | 618 | 86 | - | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Troy E. Wilson, Ph.D. | Chairman; Chief Executive Officer; President | Executive Board | 2015 | 57 |
| Kathleen Ford | Chief Operating Officer | Senior Management | 2019 | 79 |
| Teresa Bair, J.D. | Chief Legal Officer; Secretary | Senior Management | 2021 | 55 |
| Mollie Leoni, M.D. | Chief Medical Officer | Senior Management | 2025 | 48 |
| Francis Burrows, Ph.D. | Chief Scientific Officer | Senior Management | 2025 | 64 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer